This year, we had a highy successful GNC/GLC meeting during EASL 2024 in Milan, Italy which was attended by 77 members (65 in person and 12 via zoom). These members represented leaders in the field of liver disease, endocrinology, nutrition and patient representatives from most regions of the world. During the meeting, an overview of the growth and activities of the Councils and a summary of the large scale projects undertaken by the Council members were provided. These projects included the results of the Global NAFLD Stigma survey from patients and providers, the impact of the nomencalture change on evidence (mortality outcomes, NITs and PROs), initial results of the large mega-analysis of 16,000 liver biopsies from MASLD patients, Cost of Inaction about MASLD (Economic burden of MASLD) in 6 countries (US, Germany, Japan, Spain, Saudi Arabia and Brazil), NIT Threshold Global Survey and Enhancing the Implementation of MASLD/MASH Guidelines Across the Globe (EIMG). Furthermore, co-chairs of each of the 10 committees of GNC/GLC provided their reports and future plans. Academic productivity and future regional meetings were discussed.
